p53, guardian of the genome
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p53, famously known as the ‘Guardian of the genome’ plays a key role in manifestation of cellular senescence via several different mechanisms (Lane, 1992; Kastenhuber and Lowe, 2017).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Lane, 1992
In the citing paper
“p53 is an crucial tumor suppressor that is mutated in more than 50% of human cancers”
From USP10 Regulates p53 Localization and Stability by Deubiquitinating p53 (2010) · cites this paper as Lane, 1992
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
Maltzman, W., & Czyzyk, L. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1689 · Cited by 893
Research works printed but not linked: 3
- Sturzbecher, H.-W. Oncogene (in the press).
- Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. Cancer Res. 51, 6304–6311 (1991).
- Bischoff, F. Z. et al. Cancer Res. 50, 7979–7984 (1990).
Cited by
Items 101–200 of 1,031
p53 in ferroptosis regulation: The new weapon for the old guardian
Liu, Y., & Gu, W. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00943-y · Cited by 540
ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor
Chen, D., Kon, N., Li, M., Zhang, W., Qin, J., & Gu, W. (2005) · Cell · doi:10.1016/j.cell.2005.03.037 · Cited by 544
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
“It responds to cellular stress and DNA damage by inducing cell cycle arrest, apoptosis, and senescence [144]. p53 also regulates metabolism by inhibiting glycolysis and promoting OXPHOS [145].”
BackgroundOxidative stress and pulmonary fibrosis
Cheresh, P., Kim, S.-J., Tulasiram, S., & Kamp, D. W. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.021 · Cited by 530
Recent advances in apoptosis, mitochondria and drug resistance in cancer cells
Indran, I. R., Tufo, G., Pervaiz, S., & Brenner, C. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.03.010 · Cited by 526
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
Zinc deficiency, DNA damage and cancer risk
Ho, E. (2004) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2004.07.005 · Cited by 518
Murray-Zmijewski, F., Lane, D. P., & Bourdon, J.-C. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401914 · Cited by 523
Self-citationHallmarks of glycosylation in cancer
Munkley, J., & Elliott, D. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8155 · Cited by 521
Oncogenes and Tumor Suppressor Genes
Lee, E. Y. H. P., & Muller, W. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003236 · Cited by 508
“On the other hand, somatic mutations of TP53 occur in the majority of sporadic cancers. p53 responds to various cellular stress signals and is hailed as the “guardian of genome” (Lane 1992). p53 alteration is common in spontaneously immortalized murine embryonic fibroblasts (Harvey and Levine 1991).”
BackgroundMalkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
Baas, I. O., Mulder, J. R., Offerhaus, G. J. A., Vogelstein, B., & Hamilton, S. R. (1994) · The Journal of Pathology · doi:10.1002/path.1711720104 · Cited by 505
Fei, P., & El-Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206677 · Cited by 498
“P53 has been considered as the guardian of genome (Lane, 1992; Gottlieb and Oren, 1996; Ko and Prives, 1996; Levine, 1997; Prives and Hall, 1999; Morris, 2002; Tlsty, 2002), which maintains genomic stability.”
BackgroundPosttranslational Modification of p53: Cooperative Integrators of Function
Meek, D. W., & Anderson, C. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000950 · Cited by 483
“A role for p53 in transcription was proposed in 1990 on the basis of studies in yeast, and subsequently p53 was shown to have sequence-specific DNA binding activity (reviewed in Lane 1992).”
BackgroundAbegglen, L. M., Caulin, A. F., Chan, A., Lee, K., Robinson, R., Campbell, M. S., Kiso, W. K., Schmitt, D. L., Waddell, P. J., Bhaskara, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.13134 · Cited by 485
“8,26,27 Patients with LFS inherit only 1 functioning TP53 allele and may have a lifetime risk of cancer approaching 100%.”
Dissecting p53 tumor suppressor functions in vivo
Schmitt, C. A., Fridman, J. S., Yang, M., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00047-8 · Cited by 485
“…suppressor was initially identified as the “guard- ian of the genome” based on its ability to mediate a G1 arrest can accelerate tumor development in several settings, but not to the same extent as loss of p53 (Eischen et al., 2001; Yin etfollowing DNA damage (Kastan et al., 1992; Lane, 1992).”
Backgroundp53 in growth control and neoplasia
Gottlieb, T. M., & Oren, M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00019-c · Cited by 481
Leflunomide: mode of action in the treatment of rheumatoid arthritis
Breedveld, F. C., & Dayer, J.-M. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.11.841 · Cited by 485
Transcription-independent pro-apoptotic functions of p53
Moll, U. M., Wolff, S., Speidel, D., & Deppert, W. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.007 · Cited by 468
Forrester, K., Ambs, S., Lupold, S. E., Kapust, R. B., Spillare, E. A., Weinberg, W. C., Felley-Bosco, E., Wang, X. W., Geller, D. A., Tzeng, E., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2442 · Cited by 469
Myc pathways provoking cell suicide and cancer
Nilsson, J. A., & Cleveland, J. L. (2003) · Oncogene · doi:10.1038/sj.onc.1207261 · Cited by 462
“Myc triggers the Arf–p53 tumor suppressor pathway The p53 tumor suppressor has been heralded as the ‘guardian of the genome’ (Lane, 1992; White, 1996) and is the most frequently mutated gene in cancer (Zambetti and Levine, 1993). p53 functions as a sequence-specific transcription factor (Zambetti…”
BackgroundNanotoxicity assessment of quantum dots: from cellular to primate studies
Yong, K.-T., Law, W.-C., Hu, R., Ye, L., Liu, L., Swihart, M. T., & Prasad, P. N. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35392j · Cited by 460
Tomlinson, I. P. M., Novelli, M. R., & Bodmer, W. F. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14800 · Cited by 458
Bergh, J., Norberg, T., Sjögren, S., Lindgren, A., & Holmberg, L. (1995) · Nature Medicine · doi:10.1038/nm1095-1029 · Cited by 460
Cyclin G is a transcriptional target of the p53 tumor suppressor protein.
Okamoto, K., & Beach, D. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06807.x · Cited by 455
Kemp, C. J., Donehower, L. A., Bradley, A., & Balmain, A. (1993) · Cell · doi:10.1016/0092-8674(93)90461-x · Cited by 457
Esrig, D., Spruck, C., Nichols, P. W., Chaiwun, B., Steven, K. E., Groshen, S. G., Chen, S. C., Skinner, D. G., Jones, P. A., & Côté, R. J. (1993) · PubMed Central · Cited by 452
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
Liu, Y., Dong, Y., Kong, L., Shi, F., Zhu, H., & Yu, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0647-8 · Cited by 447
p53 Research: The Past Thirty Years and the Next Thirty Years
Lane, D., & Levine, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000893 · Cited by 454
Self-citationColon Cancer Stem Cells: Promise of Targeted Therapy
Todaro, M., Francipane, M. G., Medema, J. P., & Stassi, G. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.063 · Cited by 443
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Rouault, J.-P., Falette, N., Guéhenneux, F., Guillot, C., Rimokh, R., Wang, Q., Berthet, C., Moyret-Lalle, C., Savatier, P., Pain, B., et al. (1996) · Nature Genetics · doi:10.1038/ng1296-482 · Cited by 434
Ganly, I., Kirn, D. H., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C. C., et al. (2000) · PubMed · Cited by 508
Development and Selection of T Cells: Facts and Puzzles
Kisielow, P., & Von Boehmer, H. (1995) · Advances in Immunology · doi:10.1016/s0065-2776(08)60620-3 · Cited by 444
Improved survival in women with BRCA‐associated ovarian carcinoma
Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y. (2003) · Cancer · doi:10.1002/cncr.11310 · Cited by 433
Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis
Brentnall, T. A., Crispin, D. A., Rabinovitch, P. S., Haggitt, R. C., Rubin, C. E., Stevens, A. C., & Burmer, G. C. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90161-9 · Cited by 432
Homologous recombinational repair of DNA ensures mammalian chromosome stability
Thompson, L. H., & Schild, D. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00115-4 · Cited by 429
Mechanism of Action for Leflunomide in Rheumatoid Arthritis
Fox, R. I., Herrmann, M. L., Frangou, C. G., Wahl, G. M., Morris, R. E., Strand, V., & Kirschbaum, B. J. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4777 · Cited by 420
Zhu, C., Mills, K. D., Ferguson, D. O., Lee, C., Manis, J., Fleming, J., Gao, Y., Morton, C. C., & Alt, F. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00770-5 · Cited by 421
Meikrantz, W., & Schlegel, R. (1995) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240580205 · Cited by 421
Maier, P., Hartmann, L., Wenz, F., & Herskind, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010102 · Cited by 414
Viruses associated with human cancer
McLaughlin-Drubin, M. E., & Munger, K. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.12.005 · Cited by 406
Mroz, E. A., & Rocco, J. W. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2012.09.007 · Cited by 417
Azaphilones: Chemistry and Biology
Gao, J.-M., Yang, S.-X., & Qin, J.-C. (2013) · Chemical Reviews · doi:10.1021/cr300402y · Cited by 409
Thermodynamic stability of wild-type and mutant p53 core domain
Bullock, A. N., Henckel, J., DeDecker, B. S., Johnson, C. M., Nikolova, P. V., Proctor, M. R., Lane, D. P., & Fersht, A. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14338 · Cited by 405
Self-citationFan, S., El‐Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K. G., Fornace, A. J., MAGRATH, I. T., Kohn, K. W., & O'Connor, P. M. (1994) · PubMed · Cited by 454
p53 modifications: exquisite decorations of the powerful guardian
Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392
“Originally, p53 was called ‘the guardian of the genome’ (Lane, 1992) for it was found to be activated in response to various types of DNA damages.”
BackgroundHo, E., & Ames, B. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222679399 · Cited by 392
PTEN: a new guardian of the genome
Yin, Y., & Shen, W. H. (2008) · Oncogene · doi:10.1038/onc.2008.241 · Cited by 388
“…1997). p53 controls cellcycle progression, apoptosis and genomic stability (Yonish-Rouach et al., 1991; Kastan et al., 1992; Livingstone et al., 1992; Yin et al., 1992; Lowe et al., Oncogene 1993; Tlsty et al., 1994). p53 is the first to be proposed as a guardian of the genome (Lane, 1992).”
BackgroundMultiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation
Rodriguez, M. S., Desterro, J. M. P., Lain, S., Lane, D. P., & Hay, R. T. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.22.8458-8467.2000 · Cited by 389
Self-citationApoptosis in the development and treatment of cancer
Gerl, R. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh283 · Cited by 385
Huang, L. C., Clarkin, K. C., & Wahl, G. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4827 · Cited by 384
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression
Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Nature · doi:10.1038/nature05077 · Cited by 382
zur Hausen, H. (1994) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-78487-3_8 · Cited by 381
Molecular classification of gastric cancer
Chia, N.-Y., & Tan, P. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw040 · Cited by 375
p53 is associated with cellular microtubules and is transported to the nucleus by dynein
Giannakakou, P., Sackett, D. L., Ward, Y., Webster, K. R., Blagosklonny, M. V., & Fojo, T. (2000) · Nature Cell Biology · doi:10.1038/35036335 · Cited by 373
Sex differences in cancer mechanisms
Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 366
Cell Death in the Origin and Treatment of Cancer
Strasser, A., & Vaux, D. L. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.014 · Cited by 370
Langheinrich, U., Hennen, E., Stott, G., & Vacun, G. (2002) · Current Biology · doi:10.1016/s0960-9822(02)01319-2 · Cited by 371
Cooperative tumorigenic effects of germline mutations in Rb and p53
Williams, B. O., Remington, L., Albert, D. M., Mukai, S., Bronson, R. T., & Jacks, T. (1994) · Nature Genetics · doi:10.1038/ng0894-480 · Cited by 368
p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis
Kemp, C. J., Wheldon, T., & Balmain, A. (1994) · Nature Genetics · doi:10.1038/ng0994-66 · Cited by 368
Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease
Butel, J. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.405 · Cited by 371
The role of DNA breaks in genomic instability and tumorigenesis
Mills, K. D., Ferguson, D. O., & Alt, F. W. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00060.x · Cited by 361
“RAG generates DSBs in G0 or G1 of the cell cycle (177) prior to DNA replication, but p53 normally induces apoptosis in response to unrepaired DSBs (178).”
BackgroundLi-Fraumeni syndrome – a molecular and clinical review
Varley, J., Evans, D., & Birch, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.328 · Cited by 358
“Wild-type TP53 is considered to be a tumour-suppressor gene (Hollstein et al, 1991; Levine et al, 1991; Lane, 1992) and as such”
BackgroundFord, J. M., & Hanawalt, P. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.28073 · Cited by 358
Wu, H., & Lozano, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32128-2 · Cited by 361
CA 19-9: Biochemical and Clinical Aspects
Scarà, S., Bottoni, P., & Scatena, R. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-017-7215-0_15 · Cited by 351
A plausible model for the digital response of p53 to DNA damage
Ma, L., Wagner, J., Rice, J. J., Hu, W., Levine, A. J., & Stolovitzky, G. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501352102 · Cited by 356
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 349
Skin DNA photodamage and its biological consequences
Marrot, L., & Meunier, J.-R. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.12.007 · Cited by 343
Mantle cell lymphoma-- an entity comes of age
Weisenburger, D., & Armitage, J. O. (1996) · Blood · doi:10.1182/blood.v87.11.4483.bloodjournal87114483 · Cited by 343
Ford, J. M., & Hanawalt, P. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8876 · Cited by 346
p53-mediated cell death: relationship to cell cycle control.
Yonish-Rouach, E., Grunwald, D., Wilder, S., Kimchi, A., May, E., Lawrence, J. J., May, P., & Oren, M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.3.1415 · Cited by 344
Non-melanoma skin cancer: what drives tumor development and progression?
Boukamp, P. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi123 · Cited by 338
Lane, D. P. (1993) · Nature · doi:10.1038/362786a0 · Cited by 342
Self-citationApoptosis and cancer chemotherapy
Makin, G., & Dive, C. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02124-9 · Cited by 297
p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction.
Stürzbecher, H. W., Donzelmann, B., Henning, W., Knippschild, U., & Buchhop, S. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00550.x · Cited by 340
Various modes of cell death induced by DNA damage
Surova, O., & Zhivotovsky, B. (2013) · Oncogene · doi:10.1038/onc.2012.556 · Cited by 334
Tsao, A. S., Kim, E. S., & Hong, W. K. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.3.150 · Cited by 331
Nanopreparations to overcome multidrug resistance in cancer
Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.004 · Cited by 333
Donehower, L. A., & Bradley, A. (1993) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(93)90004-v · Cited by 333
A role for p53 in base excision repair
Zhou, J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.4.914 · Cited by 333
“It is believed that stress signals like DNA damage induce expression of p53, which in turn arrests the cell cycle, presumably to allow DNA repair (Lane, 1992), or drives cells to apoptosis if the damage is too extensive (Liebermann et al., 1995).”
BackgroundPancreatic adenocarcinomas frequently show p53 gene mutations.
Scarpa, A., Capelli, P., Mukai, K., Zamboni, G., Oda, T., Iacono, C., & Hirohashi, S. (1993) · PubMed · Cited by 332
Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis.
Franklin, W. A., Gazdar, A. F., Haney, J., Wistuba, I. I., La Rosa, F. G., Kennedy, T., Ritchey, D. M., & Miller, Y. E. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119748 · Cited by 330
Mycotoxins: Producing Fungi and Mechanisms of Phytotoxicity
Ismaiel, A., & Papenbrock, J. (2015) · Agriculture · doi:10.3390/agriculture5030492 · Cited by 322
“Cells with inactivated p53 might therefore survive abnormally and allow further DNA damage to accumulate [53], a situation, which favors carcinogenesis [54].”
Backgroundp53 in signaling checkpoint arrest or apoptosis
Bates, S., & Vousden, K. H. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)90004-0 · Cited by 331
Tumor-Suppressor Functions of the TP53 Pathway
Aubrey, B. J., Strasser, A., & Kelly, G. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026062 · Cited by 327
p53 Acetylation: Regulation and Consequences
Reed, S., & Quelle, D. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 332
“Through these mechanisms, p53 helps maintain genomic stability within an organism, justifying its long-held nickname “guardian of the genome” [12].”
BackgroundRNA polymerases I and III, growth control and cancer
White, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1551 · Cited by 333
The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation
SOUSSI, T. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06705.x · Cited by 332
Kaina, B. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00510-0 · Cited by 326
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin, R. L., Nemeth, E., Tran, H., Shvartsman, H. S., Cass, I. A., Narod, S. A., & Karlan, B. Y. (2000) · PubMed · Cited by 324
New concepts for an old problem: the diagnosis of endometrial hyperplasia
Sanderson, P. A., Critchley, H. O. D., Williams, A. R. W., Arends, M. J., & Saunders, P. T. K. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw042 · Cited by 323
“Owing to its role in preventing damaged DNA from dividing, p53 is considered a tumour suppressor and is often referred to as ‘the guardian of the genome’ (Lane, 1992).”
BackgroundDrach, J., Ackermann, J., Fritz, E., Krömer, E., Schuster, R., Gisslinger, H., DeSantis, M., Zojer, N., Fiegl, M., Roka, S., et al. (1998) · Blood · doi:10.1182/blood.v92.3.802 · Cited by 325
p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene
Adimoolam, S., & Ford, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202485699 · Cited by 321
McWhir, J., Selfridge, J., Harrison, D. J., Squires, S., & Melton, D. W. (1993) · Nature Genetics · doi:10.1038/ng1193-217 · Cited by 322
Abrogation of p53-Induced Apoptosis by the Hepatitis B Virus X Gene
Wang, X. W. (2003) · Hepatocellular Carcinoma · doi:10.1385/1-59259-079-9:57 · Cited by 321
Woods, D. B., & Vousden, K. H. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5141 · Cited by 319
Immortal Human Pancreatic Duct Epithelial Cell Lines with Near Normal Genotype and Phenotype
Ouyang, H., Mou, L.-J., Luk, C., Liu, N., Karaskova, J., Squire, J., & Tsao, M.-S. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64800-6 · Cited by 313
The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway.
Wang, X. W., Vermeulen, W., Coursen, J. D., Gibson, M., Lupold, S. E., Forrester, K., Xu, G., Elmore, L., Yeh, H., Hoeijmakers, J. H., et al. (1996) · Genes & Development · doi:10.1101/gad.10.10.1219 · Cited by 313
Metadata
- Authors
- Lane, D. P.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Lane, D. P.
- ORCID
- Lane, D. P.
- Venue
- Nature
- Published
- 1992-07
- Volume
- 358
- Issue
- 6381
- Pages
- 15-16
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2012053348
- Cited by
- 5,138
- References
- 19
- Citations by year
- 2026: 84 · 2025: 92 · 2024: 122 · 2023: 112 · 2022: 135 · 2021: 142 · 2020: 150 · 2019: 128 · 2018: 140 · 2017: 138 · 2016: 142 · 2015: 135 · 2014: 150 · 2013: 142 · 2012: 143
- FWCI
- 97.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- TP53, p53, TP53 mutation, cancer, genome stability, tumor suppressor
- MeSH terms
- Animals, Chromosome Mapping, DNA Damage, DNA Repair, DNA-Binding Proteins, Gene Expression Regulation, Humans, Oncogenes, Transcription Factors, Genes, Tumor Suppressor, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.